Personalised Health Motor and Cognitive Assistance System for RehAbilitation (PHRASE): A Randomized Clinical Trial

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study is a multicentric randomized controlled trial evaluating the effectiveness of digital technology, specifically a smartphone with integrated VR-and AR-based intervention, for at-home rehabilitation after stroke. The study focuses on combined motor and cognitive training for patients in the late subacute and chronic phases post-stroke. The intervention is provided through the Rehabilitation Gaming System application RGSapp, a goal-oriented, first-person virtual reality (VR) and augmented reality (AR) mobile application for upper limb rehabilitation. A total of seventy participants will be randomly assigned (1:1 ratio) to either the RGSapp intervention or conventional therapy/standard of care for six weeks. The primary outcome is motor function improvement (upper limb), assessed using the Action Research Arm Test (ARAT). Secondary outcomes include changes in cognitive function, depression, usability, adherence, validity of remote assessments, and healthcare costs.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients presenting an ischemic or intracerebral haemorrhagic stroke, ≥ 3 months post-stroke.

• Age \> 18 years old

• Moderate to mild proximal upper limb motor impairment Medical Research Council Scale (MRC \>2).

• ARAT: \<50, inclusive, to avoid ceiling effects while allowing room for improvement.

• Able to sit on a chair or a wheelchair to interact with the RGS system.

• Minimal experience with smartphone technology based on the clinician's opinion

• Willing to participate and agree to comply with the trial scheme and procedures

• Must sign an Informed Consent Form (ICF) indicating that they understand the purpose and the procedures of the study.

Locations
Other Locations
Romania
RoNeuro Institute for Neurological Research and Diagnostics
RECRUITING
Cluj-napoca
Spain
Hospital Universitari Joan XXIII de Tarragona
RECRUITING
Tarragona
Contact Information
Primary
Santiago Brandi
contact@eodyne.com
34 931389642
Backup
Anna Mura
anna3.mura@gmail.com
Time Frame
Start Date: 2025-02-21
Estimated Completion Date: 2025-08-29
Participants
Target number of participants: 70
Treatments
Experimental: Experimental Group (RGS)
The standardized intervention schedule consists of daily 20-30-minute training sessions with the RGSapp, conducted at home, including weekends, for 6 weeks. This intervention is provided in addition to the prescribed conventional therapy (Standard of Care, SoC).
No_intervention: Control Group
The control group participants will be assessed at Baseline (T0), Week 6/End of Treatment (T2), and Follow-up at Week 14 (T3). The outcome measures will be the same as in the intervention group, including assessments of motor function, cognitive function, depression, activity participation, usability, and healthcare costs. No VR or AR-based interventions will be provided to the control group during the study period.
Related Therapeutic Areas
Sponsors
Leads: Eodyne Systems SL

This content was sourced from clinicaltrials.gov